Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 0.64 |
| ▸ | MC3R | P41968 | 7/20 | 0.62 |
| ▸ | MC5R | P33032 | 7/20 | 0.62 |
| ▸ | MC1R | Q01726 | 7/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.62 |
| ▸ | PRCP | P42785 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170759 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL71981 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29904550 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL15252713 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL91103 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL70497 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL30593923 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL1920391 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL4939210 | 0.99 | MC4R (0.63) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL4939214 | 0.99 | MC4R (0.63) | MC4RMC3RMC5RMC1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240190856-A1 | MELANOCORTIN-4 RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-06-13 | — | — | US | disclosed |
| EP-4299572-A1 | MELANOCORTIN-4 RECEPTOR AGONIST | Lg Chem, Ltd. (KR) | 2024-01-03 | — | — | EP | disclosed |
| CN-109563074-B | Piperazine derivatives | 安斯泰来制药株式会社 | 2021-09-28 | — | — | CN | disclosed |
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| CN-107849018-B | Piperazine derivatives | 安斯泰来制药株式会社 | 2021-02-23 | — | — | CN | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| EP-3333165-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| WO-2005009950-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040266821-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | UJJAINWALLA FEROZE | 2004-12-30 | — | — | US | disclosed |
| US-6818658-B2 | TREATING OBESITY, DIABETES, SEXUAL DYSFUNCTION, INCLUDING ERECTILE DYSFUNCTION AND FEMALE SEXUAL DYSFUNCTION. | MERCK & CO., INC. | 2004-11-16 | — | — | US | disclosed |
| WO-2004092126-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PYRROLIDINE CARBOXYLIC ACIDS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004089307-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO. INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204398-A1 | Acylated piperazine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-10-14 | — | — | US | disclosed |
| EP-1383501-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
| WO-2002068388-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204398-A1 | Acylated piperazine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
| US-10710988-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | MC4R 2/4885MC3R 14/4885MC5R 6/4885 |
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | MC4R 1/4885MC3R 2/4885MC5R 3/4885 |
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | AQP3, SLC6A7, ABCG2 | MC4R 2367/4885MC3R 1834/4885MC5R 1441/4885 |
| US-20240190856-A1 | MELANOCORTIN-4 RECEPTOR AGONIST | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | GPR4, MC4R, TRPC4 | MC4R 2/4885MC3R 14/4885MC5R 6/4885 |
| US-20040266821-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.